Paris-based Sanofi and Houston-based The University of Texas MD Anderson Cancer Center entered a five-year strategic partnership to develop immune therapies and targeted cancer treatments.
The immuno-oncology therapy CAR-T utilizes specific types of immune cells, T-cells, which are drawn from the cancer patient, supercharged and infused back into the patient. Now, The University of Texas MD Anderson Cancer Center has developed a slightly different approach using a different type of immune cell called Natural Killer (NK) cells.
The Department of Justice leveled more charges against members of the U.S. science community who have alleged ties to China.
With an increased need for the development of vaccines for various illnesses, Pfizer responded with the launch of the company’s Vaccines Division’s Centers of Excellence Network.
The U.S. Senate confirmed Stephen Hahn as commissioner of the U.S. Food and Drug Administration in a 72-18 vote.
In the halls of MD Anderson Cancer Center, Vitrakvi is known for having a “Lazarus effect” in some patients because the drug can reverse late-stage cancer that has defied all other treatment options.